Qiagen (QGEN) has partnered with ID Solutions to improve access to advanced genetic testing tools for cancer research.

The collaboration combines global expertise, automation and manufacturing capabilities to expand the availability of digital polymerase chain reaction tests, which help analyze DNA for scientific studies, Qiagen said Thursday in a statement.

As part of the agreement, ID Solutions of France will develop and supply these digital PCR tests for non-clinical research use on Qiagen's QIAcuity platforms.

Qiagen of the Netherlands plans to commercialize the assay kits in Europe initially with possible expansion into other markets.

Financial details of the collaboration weren't disclosed.